Prognostic model built on blood-based biomarkers in patients with metastatic colorectal cancer.
Prognostic model built on blood-based biomarkers in patients with metastatic colorectal cancer.
复制标题
DOI：
10.7314/apjcp.2014.15.17.7327
复制
发表时间：
2014
期刊：
影响因子：
--
通讯作者：
Wenzhuo He;Chang Jiang;Chen-xi Yin;Guifang Guo;Ru-Ming Rong;Hui-juan Qiu;Xu-xian Chen;Bei Zhang
中科院分区：
文献类型：
--
作者：
Wenzhuo He;Chang Jiang;Chen-xi Yin;Guifang Guo;Ru-Ming Rong;Hui-juan Qiu;Xu-xian Chen;Bei Zhang
BACKGROUND We had previously showed that the neutrophil lymphocyte ratio (NLR), γ-glutamyl transpeptidase (GGT) and carcinoembryonic antigen (CEA) are prognostic factors for metastatic colorectal cancer (mCRC) patients. In this study we developed a prognostic model based on these three indices. MATERIALS AND METHODS A total of 243 patients who were initially diagnosed as mCRC between 2005 and 2010 in the Sun Yat-sen University Cancer Center were studied. The endpoint was overall survival (OS). RESULTS NLR>3, elevated GGT and elevated CEA were confirmed as independent risk factors which could predict poor prognosis. Patients could be divided into three groups according to the number of risk factors they had. Those with two or three were defined as the high risk group, individuals with one risk factor as the modest risk group and patients without risk factor as the low risk group. The OS values for these three groups were 16.2 months (2.80~68.8), 24.2 months (4.07~79.0), and 37.2 months (12.6~87.8), respectively (p<0.001). CONCLUSIONS We developed a simple but useful model based on NLR, GGT and CEA to provide prognostic information to clinical practice in highly selected mCRC patients. Further prospective and multi-center studies are warranted to test our model.
